4SC AG

Report Publication Announcement • Aug 3, 2017

News Details

Corporate | 3 August 2017 07:30

4SC AG: Conference call to be hosted on 10 August 2017 to present the half-year financial report 2017

DGAP-News: 4SC AG / Key word(s): Half Year Results/Quarter Results

03.08.2017 / 07:30

The issuer is solely responsible for the content of this announcement.

---

4SC AG: Conference call to be hosted on 10 August 2017 to present the half-year financial report 2017

Planegg-Martinsried, Germany, 3 August 2017 – 4SC AG (4SC, FSE Prime Standard: VSC) will publish its half-year financial report on 10 August 2017. On this day, the Management of 4SC AG will host a conference call at 2 pm CEDT (8 am EDT) to inform about important developments in the reporting period and beyond.

Investors, financial analysts, and journalists interested in participating in the conference call can access via the following telephone numbers:

Date:	10 August 2017
Time:	2 p.m. CEDT (8 a.m. EDT)
Phone Numbers:	+49 89 2030 35709 (Germany)
	+44 330 336 9105 (United Kingdom)
	+1 719 325 4756 (USA)
Conference ID:	5047397

A presentation document supporting the conference call will be available on 10 August 2017, at 4SC’s website . After the event, a replay can be accessed from there as well.

– Announcement ends –

Further information

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life. 4SC’s pipeline is protected by a comprehensive portfolio of patents and comprises promising products that are in various stages of preclinical and clinical development. 4SC’s core assets include resminostat , 4SC-202 and 4SC-208 .

4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. Founded in 1997, 4SC had 45 employees as of 12 June 2017. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

4SC Corporate Communications & Investor Relations

Anna Niedl, Ph.D., anna.niedl@4sc.com , +49 89 700763-66

Wolfgang Güssgen, wolfgang.guessgen@4sc.com , +49 89 700763-73

---

03.08.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de

---

Language:	English
Company:	4SC AG
	Fraunhoferstr. 22
	82152 Planegg-Martinsried
	Germany
Phone:	+49 89 700763-0
Fax:	+49 89 700763-29
E-mail:	public@4sc.com
Internet:	www.4sc.com
ISIN:	DE000A14KL72
WKN:	A14KL7
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

End of News	DGAP News Service